Gland Pharma shares surged after strong Q1 results and positive commentary from brokerages citing a turnaround at its European unit Cenexi. EBITDA margins expanded to 24.4%, and net profit rose 50% YoY. Despite weak U.S. sales, growth in Europe and new launches supported the outlook. Brokerages raised earnings estimates and targets, expecting further gains as Cenexi scales profitability.
Is the smallcap rally a trap? Only 37% of stocks are outperforming their benchmark
India’s recent smallcap surge indicates that less stock is outpacing the benchmark index, revealing a narrowing group of successful stocks boosting overall returns. Conversely, largecap
August 25, 2026